MarketPulse

thyroid eye disease

3 articles
The Motley FoolThe Motley Fool··Andy Gould

Kopp Family Office Dumps $3.5M Viridian Stake as Biotech Stock Tanks 50%

Kopp Family Office exits $3.5M Viridian stake as stock plummets 50% following disappointing Phase 3 data and Amgen's superior competing results.
AMGNVEAVRDNAGGFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Immunovant's Batoclimab Misses Phase 3 Primary Endpoint in Thyroid Eye Disease

Immunovant's batoclimab failed to meet primary efficacy targets in Phase 3 thyroid eye disease trials, though safety remained consistent. Company pivots focus to Graves' disease studies.
IMVTclinical trialthyroid eye disease
The Motley FoolThe Motley Fool··Jonathan Ponciano

Major Fund Liquidates $69M Viridian Position Despite 75% Annual Rally

Commodore Capital liquidates its entire $69M Viridian position despite the stock's 75% annual rally, signaling strategic reallocation ahead of anticipated FDA decisions.
VRDNALKSTYRAbiotech portfolio exitposition liquidation